Development and Evaluation of Rapid and Accurate CRISPR/Cas13-Based RNA Diagnostics for Pneumocystis jirovecii Pneumonia

Yangqing Zhan, Xiaoqing Gao, Shaoqiang Li, Yeqi Si, Yuanxiang Li, Xu Han, Wenjun Sun, Zhengtu Li, Feng YeFrontiers in Cellular and Infection Microbiology 2022 · DOI

TL;DR

Researchers have developed a novel diagnostic tool, RapidCasD, that combines RNA amplification with CRISPR/Cas13 technology to rapidly and accurately detect Pneumocystis jirovecii pneumonia (PJP). This new method shows promise in distinguishing between active infection and colonization, a significant challenge with current diagnostic approaches.

What Problem Does This Paper Address?

Pneumocystis jirovecii pneumonia (PJP) is a serious opportunistic infection, particularly in immunocompromised individuals, often leading to significant mortality. Diagnosing PJP is clinically challenging due to the difficulty in culturing the pathogen and limitations of existing diagnostic methods. Traditional methods like immunostaining lack sensitivity, while polymerase chain reaction (PCR) primarily detects DNA. Detecting DNA can be problematic as it may persist long after an infection has cleared, making it difficult to differentiate between active infection and colonization. This ambiguity can lead to misdiagnosis and inappropriate treatment. The paper aims to address this by developing a rapid, sensitive, and specific diagnostic tool that targets RNA, offering a clearer distinction between infection and colonization.

Methods

The core of the developed diagnostic system, termed RapidCasD, involves two key steps:

  1. Transcription Mediated Amplification (TMA): This isothermal amplification technique is used to specifically amplify RNA from extracted samples. TMA is chosen for its ability to amplify RNA without requiring a reverse transcription step, making it a direct RNA amplification method. The researchers screened multiple primer pairs to optimize TMA for the P. jirovecii-mitochondrial large subunit ribosomal RNA (mtLSUrRNA) gene, identifying a highly effective pair (F3+R1). They also optimized the amplification time to 50 minutes for maximal signal.
  2. CRISPR/Cas13a Detection: Following TMA, the amplified RNA is detected using the CRISPR/Cas13a system. This system utilizes a guide RNA (crRNA) to direct the Cas13a enzyme to cleave a specific RNA target. Upon cleavage, a fluorescent reporter molecule is released, generating a detectable signal. The researchers screened ten different crRNAs to identify the most effective one (crRNA #2) for detecting P. jirovecii. This step is crucial for achieving high specificity.

The entire process, from RNA extraction to fluorescence signal detection, can be completed within approximately 60 minutes.

Datasets

The study utilized surplus bronchial alveolar lavage fluid (BALF) samples collected from patients suspected of PJP. A total of 62 valid BALF samples were analyzed. These samples were collected from non-HIV patients at the First Affiliated Hospital of Guangzhou Medical University between April 2019 and April 2021. The study also included samples from common respiratory pathogens for specificity testing.

Key Insights and Ideas

  • RNA as a Superior Target for PJP Diagnosis: By targeting RNA instead of DNA, the RapidCasD system offers a significant advantage in distinguishing between active infection and colonization. RNA is generally less stable than DNA and is more indicative of current biological activity.
  • CRISPR/Cas13a's Specificity Power: The CRISPR/Cas13a system, when combined with a well-designed crRNA, provides remarkable specificity. This was demonstrated by the lack of cross-reactivity with other respiratory pathogens and the ability to differentiate between RNA and DNA targets.
  • TMA Enhances Sensitivity: While CRISPR/Cas13a is specific, it may have limitations in sensitivity on its own. Combining it with TMA, an isothermal amplification method, significantly boosts the assay's ability to detect low pathogen loads, achieving single-copy sensitivity.
  • A Rapid, Integrated Diagnostic Workflow: The development of a streamlined workflow integrating TMA and CRISPR/Cas13a detection allows for results within an hour, a substantial improvement over traditional methods that can take much longer or require specialized equipment and expertise.

Key Results

  • Sensitivity: The RapidCasD assay demonstrated a lower limit of detection of approximately 2 copies/µL of transcribed RNA templates.
  • Specificity: The assay showed no cross-reactivity with a panel of common respiratory pathogens, including bacteria and fungi. Furthermore, experiments confirmed that the assay specifically detects RNA and not DNA.
  • Performance on Clinical Samples: In a preliminary evaluation of 62 surplus BALF samples, RapidCasD achieved a sensitivity of 78.9% and a specificity of 97.7% for diagnosing PJP. This is compared to qPCR, which showed 100% sensitivity but only 65.1% specificity.
  • Distinguishing Infection from Colonization: The study found that while qPCR showed a significant overlap in Ct values between PJP patients and those colonized with P. jirovecii, RapidCasD's higher specificity suggests it is better at differentiating between these two states.
  • Speed: The entire diagnostic process can be completed in under 60 minutes.

Limitations and Future Work

The authors acknowledge several limitations:

  • Invasive Procedure: The current method relies on BALF, which is obtained through an invasive procedure. Future work should explore the application of RapidCasD to non-invasive specimens like sputum, oral washes, or throat swabs.
  • Sample Preservation: The study used preserved surplus samples, and potential RNA degradation during storage could have impacted sensitivity.
  • Patient Cohort: The study primarily included mild cases and a limited number of patients requiring ICU care or non-invasive ventilation. The sample size was also relatively small.
  • Non-HIV Population: The study focused on non-HIV patients, so the applicability to HIV-positive individuals needs further investigation.

Future work should focus on validating these findings in larger, prospective studies across diverse patient populations and exploring the use of non-invasive sample types to broaden the diagnostic utility of this promising technology.

Summary updated

Abstract

Our study demonstrates that the CRISPR/Cas13-based diagnostics technique has good performance for the accurate and specific diagnosis of <i>Pneumocystis jirovecii</i> pneumonia.
BibTeX
@inproceedings{zhan2022development,
  author = {Yangqing Zhan and Xiaoqing Gao and Shaoqiang Li and Yeqi Si and Yuanxiang Li and Xu Han and Wenjun Sun and Zhengtu Li and Feng Ye},
  title = {{Development and Evaluation of Rapid and Accurate CRISPR/Cas13-Based RNA Diagnostics for Pneumocystis jirovecii Pneumonia}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2022},
  doi = {10.3389/fcimb.2022.904485},
}
Figure